| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and cash equivalents | $1.1M-65.8% | $3.3M-84.3% | $20.7M+90.8% | $10.9M |
| Accounts receivable, net | $318K+187.4% | $111K-54.4% | $243K+234.1% | $73K |
| Prepaid expenses | $434K+28.1% | $339K-35.0% | $521K-33.6% | $785K |
| Other current assets | $192K-43.9% | $343K-4.7% | $360K-19.5% | $448K |
| Total Current Assets | $2.1M-49.2% | $4.1M-81.4% | $21.9M+79.5% | $12.2M |
| Property and equipment, net | $4.0M-9.1% | $4.4M-19.8% | $5.5M+2.4% | $5.4M |
| Operating lease right-of-use assets | $496K-17.3% | $600K+9.2% | $550K-11.3% | $619K |
| Intangible assets, net | $317K+0.9% | $314K+1213.5% | $24K-78.4% | $111K |
| Total Assets | $6.9M-26.6% | $9.4M-66.4% | $28.0M+52.8% | $18.3M |
| Accounts payable | $2.9M+5.5% | $2.8M-13.9% | $3.2M+5.5% | $3.0M |
| Accrued liabilities | $4.2M+21.1% | $3.5M-11.5% | $3.9M+36.8% | $2.9M |
| Deferred revenue | $354K+53.8% | $230K+115.8% | $107K-98.9% | $10.0M |
| Management and directors' fees payable | $81K+169.0% | $30K-49.5% | $60K-16.2% | $71K |
| Current portion of long-term debt | $891K+3.5% | $860K-28.7% | $1.2M+13.2% | $1.1M |
| Current portion of financing lease liabilities | $54K+16.3% | $47K-3.8% | $49K+5.6% | $46K |
| Current portion of operating lease liabilities | $250K+12.9% | $222K+11.3% | $199K-18.7% | $245K |
| Current portion of grants repayable | $117K+92.0% | $61K+9.2% | $56K+33.5% | $42K |
| Warrant liability | $21K-78.6% | $98K-22.7% | $127K | $0 |
| Derivative liability | $914K | $0 | — | — |
| Current portion of convertible note payable, net | $2.4M | $0 | — | — |
| Total Current Liabilities | $12.2M+57.0% | $7.8M-12.9% | $8.9M-48.6% | $17.4M |
| Long-term debt, net of current portion | $5.8M+47.2% | $4.0M+9.0% | $3.6M+30.4% | $2.8M |
| Deferred revenue, net of current portion | $21.9M-3.2% | $22.7M-1.0% | $22.9M | — |
| Finance lease liabilities, net of current portion | $318K-3.2% | $328K-17.9% | $400K-8.3% | $436K |
| Operating lease liabilities, net of current portion | $277K-32.7% | $411K+8.6% | $378K-5.5% | $400K |
| Grants repayable, net of current portion | $474K+31.1% | $361K-14.5% | $423K | — |
| Convertible note payable, net of current portion | $1.4M | $0 | — | — |
| Total Liabilities | $42.5M+19.7% | $35.5M-3.2% | $36.7M+71.1% | $21.4M |
| Common stock Authorized: 325,000,000 shares of common stock, at $0.001 par value Issued and outstanding: 125,779,769 shares and 96,097,485 shares, respectively | $126K+30.9% | $96K+17.3% | $82K+41.5% | $58K |
| Additional paid-in capital | $218.8M+7.2% | $204.2M+5.0% | $194.4M+18.3% | $164.4M |
| Accumulated other comprehensive income | -$295K-176.5% | $386K+58.1% | $244K+7.4% | $227K |
| Accumulated deficit | -$252.9M-10.2% | -$229.5M-13.3% | -$202.6M-21.1% | -$167.3M |
| Total VolitionRx Limited Stockholders' Deficit | -$34.2M-37.5% | -$24.9M-219.2% | -$7.8M-203.0% | -$2.6M |
| Non-controlling interest | -$1.3M-12.2% | -$1.2M-31.9% | -$910K-64.9% | -$552K |
| Total Stockholders' Deficit | -$35.6M-36.3% | -$26.1M-199.7% | -$8.7M-178.6% | -$3.1M |
| Total Liabilities and Stockholders' Deficit | $6.9M-26.6% | $9.4M-66.4% | $28.0M+52.8% | $18.3M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.